Citations

Clear

246 citation(s) found for "Study, Alfa".

Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson's disease
Nuytemans, Karen , Inchausti, Vanessa, Beecham, Gary W. , Wang, Liyong , Dickson, Dennis W. , Trojanowski, John Q. , Mash, Deborah C. , Frosch, Matthew P. , Montine, Thomas J. , Dawson, Ted M. , Martin, Eden R. , Scott, William K. , Vance, Jeffery M. , Lee, Virginia M.‐Y. , Foroud, Tatiana , Honig, Lawrence S. , Dickson, Dennis W

Mayo Clinic

Movement Disorders | February 26, 2014 | Volume: 29 | Issue: 6 | Pages: 827-830

10.1002/mds.25838 | PMID 24573903 Get It

ABSTRACTBackgroundWe have reported that intermediate repeat lengths of the C9ORF72 repeat are a risk factor for Parkinson's disease (PD) in a clinically diagnosed data set. Because 10% to 25% of clinically diagnosed PD have different diagnoses upon autopsy, we hypothesized that this may reflect phenotypic heterogeneity or concomitant pathology of other neurodegenerative disorders.MethodsWe screened 488 autopsy‐confirmed PD cases for expansion haplotype tag rs3849942T. In 196 identified haplotype carriers, the C9ORF72 repeat was genotyped using the repeat‐primed polymerase chain reaction assay.ResultsNo larger (intermediate or expanded) repeats were found in these autopsy‐confirmed PD samples. This absence of larger repeats is significantly different from the frequency in clinically diagnosed datasets (P = 0.002).ConclusionsOur results suggest that expanded or intermediate C9ORF72 repeats in clinically diagnosed PD or parkinsonism might be an indication of heterogeneity in clinically diagnosed PD cases. Further studies are needed to elucidate the potential contribution of the C9ORF72 repeat to autopsy‐confirmed PD. © 2014 International Parkinson and Movement Disorder Society
Revisiting the framework of the National Institute on Aging‐Alzheimer's Association diagnostic criteria
Carrillo, María C. , Dean, Robert A., Nicolas, François, Berman, Robert , Khachaturian, Zaven S., Bain, Lisa J. , Schindler, Rachel, Miller, David S. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | November 14, 2013 | Volume: 9 | Issue: 5 | Pages: 594-601

10.1016/j.jalz.2013.05.1762 | PMID 24007744 Get It

Abstract In 2011, the National Institute on Aging and the Alzheimer's Association (NIA‐AA) proposed revising the criteria for diagnosing Alzheimer's disease (AD), which had been established more than 25 years earlier by the National Institute on Neurologic and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA), now called the Alzheimer's Association. The NIA‐AA initiative also built upon research criteria for AD proposed by the International Working Group (IWG) in 2007 and updated in 2010. These efforts to revise the criteria reflect the need to improve diagnostic accuracy, facilitate clinical trials, and establish a common set of criteria that are universally accepted across domains of clinical practice, research, and drug development. To ensure that the proposed NIA‐AA criteria remain as current as possible, the Alzheimer's Association Research Roundtable convened a meeting in Washington, DC, on October 1 and 2, 2012, bringing together international stakeholders from industry, academia, and regulatory agencies to identify areas of agreement and research gaps respective of NIA‐AA criteria and IWG recommendations.